Researchers uncover genetic gains and losses in Tourette syndrome
NIH-funded study finds new clues to brain disorder. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - June 21, 2017 Category: American Health Source Type: news
Researchers uncover genetic gains and losses in Tourette syndrome
(NIH/National Institute of Neurological Disorders and Stroke) Researchers have identified structural changes in two genes that increase the risk of developing Tourette syndrome, a neurological disorder characterized by involuntary motor and vocal tics. The study, published in the journal Neuron, was supported by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 21, 2017 Category: International Medicine & Public Health Source Type: news
Medical News Today: Tic disorders: Causes, types, and diagnosis
Tics are involuntary, repetitive sounds or movements. We take a closer look at three types of tic disorders: vocal, motor, and Tourette's syndrome. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 16, 2017 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news
Behavioral Therapy Now First Line for Tics Behavioral Therapy Now First Line for Tics
Practicing habit reversal therapy is just as effective as drug therapy for tics and Tourette syndrome, new research suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Tourette-like tics vanish in mice treated with histamine
Yale scientists produced increased grooming behavior in mice that may model tics in Tourette syndrome and discovered these behaviors vanish when histamine — a neurotransmitter most commonly associated with allergies — is introduced into their brains. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 5, 2017 Category: Universities & Medical Training Tags: Yale News Source Type: news
Neurocrine ’s Ingrezza fails to meet primary endpoint in Phase II trial for Tourette syndrome
US-based biotechnology firm Neurocrine Biosciences ’ Ingrezza (valbenazine) has failed to meet the primary endpoint in its Phase II T-Force GREEN clinical trial to treat Tourette syndrome. (Source: Drug Development Technology)
Source: Drug Development Technology - May 24, 2017 Category: Pharmaceuticals Source Type: news
Gov. Deal signs medical marijuana expansion
Legislation Gov. Nathan Deal signed Tuesday will add six illnesses to the list of medical conditions that qualify for treatment in Georgia with a form of medical marijuana.
Senate Bill 16 expands access to cannabis oil to Georgians suffering from Tourette's syndrome; autism spectral disorder in the case of adults and severe autism in children; epidermolysis bullosa; severe or end stage Alzheimer's disease, AIDS or peripheral neuropathy; and hospice patients who have been authorized by their physicians… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 9, 2017 Category: Biotechnology Authors: Dave Williams Source Type: news
Gov. Deal signs medical marijuana expansion
Legislation Gov. Nathan Deal signed Tuesday will add six illnesses to the list of medical conditions that qualify for treatment in Georgia with a form of medical marijuana.
Senate Bill 16 expands access to cannabis oil to Georgians suffering from Tourette's syndrome; autism spectral disorder in the case of adults and severe autism in children; epidermolysis bullosa; severe or end stage Alzheimer's disease, AIDS or peripheral neuropathy; and hospice patients who have been authorized by their physicians… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 9, 2017 Category: American Health Authors: Dave Williams Source Type: news
First clear-cut risk genes for Tourette disorder revealed
Tourette disorder afflicts as many as one person in a hundred worldwide with potentially disabling symptoms including involuntary motor and vocal tics. However, researchers have so far failed to determine the cause of the disorder, and treatments have only limited effectiveness, in part because the genetics underlying the disorder have remained largely a mystery. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 3, 2017 Category: Science Source Type: news
Genetic basis of some cases of Tourette ’s disorder discovered
Researchers have discovered four genes that are associated with a higher risk of developing Tourette ’s disorder, although variants in as many as 400 genes contribute to the origins of the complex neurological condition, which is marked by motor and vocal tics. A consortium of researchers from multiple institutions analyzed the protein-coding genes of more than 500 Tourette patients and unaffecte d parents and published the results May 3 in the journal Neuron (Source: Yale Science and Health News)
Source: Yale Science and Health News - May 3, 2017 Category: Universities & Medical Training Tags: Yale News Source Type: news
Kim Dutton Advances at Arkansas Children's Foundation (Movers & Shakers)
Kim Dutton has been promoted to executive director of philanthropy at Arkansas Children’s Foundation in Little Rock.
She joined the foundation team in 2012 as a major gifts officer focused on developing and expanding the foundation’s presence in the region.
Terri Bunch has been hired as chief nursing officer at White River Medical System in Batesville.
Bunch has several years of experience in health care as well as previous experience as a chief nursing officer. She has worked in senior-level positions with for-profit and not-for-profit organizations in rural and urban communities before accepting this positio...
Source: Arkansas Business - Health Care - April 24, 2017 Category: American Health Source Type: news
Abide doses first patient in Phase Ib trial of ABX-1431 to treat tourette syndrome
US-based Abide Therapeutics has started dosing patients in a Phase Ib clinical trial of ABX-1431 for the treatment of tourette syndrome (TS). (Source: Drug Development Technology)
Source: Drug Development Technology - April 19, 2017 Category: Pharmaceuticals Source Type: news
Deep Brain Stimulation May Ease Tourette Tics
But neurology experts agree that more research is needed (Source: WebMD Health)
Source: WebMD Health - April 12, 2017 Category: Consumer Health News Source Type: news
Deep Brain Stimulation May Ease Tourette'Tics '
But neurology experts agree that more research is neededSource: HealthDay
Related MedlinePlus Page: Tourette Syndrome (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 11, 2017 Category: Consumer Health News Source Type: news
Deep Brain Stimulation May Ease Tourette'Tics '
TUESDAY, April 11, 2017 -- Some young people with severe cases of Tourette syndrome may benefit from having electrodes implanted in the brain, a small study suggests.
The procedure, known as deep brain stimulation (DBS), has long been used to treat... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 11, 2017 Category: Journals (General) Source Type: news
